Breaking Finance News

Zacks Investment Research downgraded Natus Medical Inc (NASDAQ:BABY) to Hold in a report released today.

Zacks Investment Research has downgraded Natus Medical Inc (NASDAQ:BABY) to Hold in a report released on 09/28/2016.

Yesterday Natus Medical Inc (NASDAQ:BABY) traded 1.45% higher at $39.89. The company’s 50-day moving average is $40.37 and its 200-day moving average is $36.81. The last stock close price is up 8.38% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,110,466 shares of the stock were exchanged, up from an average trading volume of 301,542

Recent Performance Chart

Natus Medical Inc (NASDAQ:BABY)

Natus Medical Inc has price-earnings ratio of 34.39 with a one year low of $29.54 and a one year high of $51.05 and has a total market value of $0.

A total of 2 brokers have issued a report on the stock. One analyst rating the company a strong buy, 2 brokerages rating the stock a buy, 0 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $42.00.

Brief Synopsis On Natus Medical Inc (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *